1. Home
  2. VVPR vs IFRX Comparison

VVPR vs IFRX Comparison

Compare VVPR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VivoPower International PLC

VVPR

VivoPower International PLC

N/A

Current Price

$1.94

Market Cap

24.2M

Sector

Utilities

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$0.95

Market Cap

60.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VVPR
IFRX
Founded
2014
2007
Country
United Kingdom
Germany
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2M
60.6M
IPO Year
2016
2017

Fundamental Metrics

Financial Performance
Metric
VVPR
IFRX
Price
$1.94
$0.95
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
1.2M
178.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$0.71
52 Week High
$8.88
$1.94

Technical Indicators

Market Signals
Indicator
VVPR
IFRX
Relative Strength Index (RSI) 44.21 56.15
Support Level $1.20 $0.96
Resistance Level $2.90 $1.16
Average True Range (ATR) 0.29 0.06
MACD -0.04 0.01
Stochastic Oscillator 11.60 82.45

Price Performance

Historical Comparison
VVPR
IFRX

About VVPR VivoPower International PLC

Vivopower International PLC is a sustainable energy solutions B Corporation specializing in electric solutions for customized and ruggedized fleet applications, battery and microgrids, solar, and critical power technology and services. The company's core purpose is to provide turnkey decarbonization solutions that help customers progress toward net-zero carbon status. VivoPower operates across five reportable segments: Electric Vehicles, Sustainable Energy Solutions, Solar Development, Digital Assets, and Corporate Office, with personnel and operations in Australia, the Netherlands, the United Kingdom, the United States, and the Philippines.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: